All articles
Evidence-led research on repurposed compounds and the protocols people actually ask about — cited to primary literature and reviewed for accuracy.
Ivermectin Nanocrystals Mimic Platelets for Enhanced Breast Cancer Targeting (2026)
A 2026 study shows platelet-membrane-coated ivermectin nanocrystals selectively target triple-negative breast cancer cells and enhance immune infiltration in preclinical models. This biomimetic approach addresses solubility and toxicity barriers.
Ivermectin Modulates Growth Signals in Hormone-Resistant Tumors
A 2026 PLOS One study showed ivermectin suppresses estrogen receptor, HER2, and TGF-β signaling in endocrine-resistant breast cancer cells, suggesting potential to prevent or reverse resistance.
NIH Registers Phase 2 ICONIC Trial: Ivermectin + Immune Checkpoint Inhibitors for Cancer
The NIH has registered a new Phase 2 clinical trial (NCT07487805, ICONIC) to evaluate ivermectin combined with immune checkpoint inhibitors in adult solid tumor patients. The trial is not yet recruiting, with an estimated start of September 2026.
Curcumin Analog CCA-1.1 Kills TNBC Cells in 3D Spheroid Culture
A 2026 study in the Asian Pacific Journal of Cancer Prevention tested a synthetic curcumin derivative (CCA-1.1) in a 3D spheroid model of triple-negative breast cancer, showing dose-dependent inhibition and altered EMT markers.
Mebendazole Chemotherapy Combo Enhances Macrophage Modulation in Cancer
A 2026 Oncology Reports study shows mebendazole enhances chemotherapy and promotes macrophage polarization from M2 to M1 in patient tumor models and a mouse colon cancer model.
Curcumin + Benzimidazole Nanocomplex Shows Promise in Liver Cancer
A 2026 Scientific Reports study demonstrates that a microbial levan enhances hepatic retention and antitumor activity of a PEGylated benzimidazole-curcumin nanocomplex in experimental liver cancer.
Metabolic Therapy + Repurposed Drugs in HR+ Breast Cancer: A 2026 Case Report
A 2026 Frontiers in Oncology case report documents a patient with metastatic HR+ breast cancer who achieved near-complete response using metabolic therapy combined with repurposed drugs.
Mebendazole Inhibits PELI3 to Restore Proapoptotic Signaling in Lung Cancer
Mebendazole inhibits PELI3 E3 ubiquitin ligase expression in HCC827 and A549 non-small cell lung cancer cells, increasing TRADD protein levels and restoring proapoptotic autophagy.
Curcumin as a Molecular Synergy Amplifier in Cancer Therapy
A new 2026 review in Pharmaceutics proposes curcumin as a molecular synergy amplifier whose clinical utility depends on mechanistic complementarity and pharmacokinetic synchronization with co-administered therapies.
Mebendazole Enhances Chemotherapy and Reprograms Macrophages in Patient Tumor Models
Mebendazole shows modest single-agent cytotoxicity in patient-derived AML, ovarian, colorectal and renal cancer cells, but enhances irinotecan and cisplatin effects. In a mouse CT26 colon cancer model, mebendazole promotes M2→M1 macrophage polarization.
Fenbendazole
Fenbendazole for Liver Cancer (Hepatocellular Carcinoma): Research Review
Does fenbendazole help hepatocellular carcinoma? A look at the preclinical anti-tumour signals, the documented liver-injury cases, and sensible monitoring.
Monensin Demonstrates Antitumor Activity in Diverse Malignancies (2026 Preclinical Overview)
A 2026 review in Molecular Biology Reports summarizes preclinical evidence that monensin, a veterinary ionophore, demonstrates antitumor activity across breast, prostate, pancreatic, ovarian, renal, liver, thyroid, and brain malignancies.
Nothing here yet.